PMID- 23630415
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20221207
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 7
DP  - 2013
TI  - Effects of vildagliptin (Galvus(R)) therapy in patients with type 2 diabetes 
      mellitus after heart transplantation.
PG  - 297-303
LID - 10.2147/DDDT.S43092 [doi]
AB  - BACKGROUND: Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients 
      after heart transplantation (HTx) and is associated with adverse long-term 
      outcomes. METHODS: The retrospective study reported here analyzed the effects of 
      vildagliptin therapy in stable patients post-HTx with T2DM and compared these 
      with control patients for matched-pairs analysis. A total of 30 stable patients 
      post-HTx with T2DM were included in the study. Fifteen patients (mean age 58.6 +/- 
      6.0 years, mean time post-HTx 4.9 +/- 5.3 years, twelve male and three female) were 
      included in the vildagliptin group (VG) and 15 patients were included in the 
      control group (CG) (mean age 61.2 +/- 8.3 years, mean time post-HTx 7.2 +/- 6.6 
      years, all male). RESULTS: Mean glycated hemoglobin (HbA1c) in the VG was 7.4% +/- 
      0.7% before versus 6.8% +/- 0.8% after 8 months of vildagliptin therapy (P = 0.002 
      vs baseline). In the CG, HbA1c was 7.0% +/- 0.7% versus 7.3% +/- 1.2% at follow-up (P 
      = 0.21). Additionally, there was a significant reduction in mean blood glucose in 
      the VG, from 165.0 +/- 18.8 mg/dL to 147.9 +/- 22.7 mg/dL (P = 0.002 vs baseline), 
      whereas mean blood glucose increased slightly in the CG from 154.7 +/- 19.7 mg/dL 
      to 162.6 +/- 35.0 mg/dL (P = 0.21). No statistically significant changes in body 
      weight (from 83.3 +/- 10.8 kg to 82.0 +/- 10.9 kg, P = 0.20), total cholesterol 
      (1.5%, P = 0.68), or triglyceride levels (8.0%, P = 0.65) were seen in the VG. No 
      significant changes in immunosuppressive drug levels or dosages were observed in 
      either group. CONCLUSION: Vildagliptin therapy significantly reduced HbA1c and 
      mean blood glucose levels in post-HTx patients in this study with T2DM and did 
      not have any negative effects on lipid profile or body weight. Thus, vildagliptin 
      therapy presented an interesting therapeutic approach for this selected patient 
      cohort.
FAU - Gueler, Ibrahim
AU  - Gueler I
AD  - Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
FAU - Mueller, Susanne
AU  - Mueller S
FAU - Helmschrott, Matthias
AU  - Helmschrott M
FAU - Oeing, Christian U
AU  - Oeing CU
FAU - Erbel, Christian
AU  - Erbel C
FAU - Frankenstein, Lutz
AU  - Frankenstein L
FAU - Gleissner, Christian
AU  - Gleissner C
FAU - Ruhparwar, Arjang
AU  - Ruhparwar A
FAU - Ehlermann, Philipp
AU  - Ehlermann P
FAU - Dengler, Thomas J
AU  - Dengler TJ
FAU - Katus, Hugo A
AU  - Katus HA
FAU - Doesch, Andreas O
AU  - Doesch AO
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Lipids)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (hemoglobin A1c protein, human)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/adverse effects/*analogs & derivatives/therapeutic use
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Heart Transplantation/*adverse effects
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Nitriles/adverse effects/*therapeutic use
MH  - Pyrrolidines/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Vildagliptin
PMC - PMC3623547
OTO - NOTNLM
OT  - glycated hemoglobin
OT  - immunosuppression
OT  - mean blood glucose
EDAT- 2013/05/01 06:00
MHDA- 2013/12/16 06:00
PMCR- 2013/04/08
CRDT- 2013/05/01 06:00
PHST- 2013/05/01 06:00 [entrez]
PHST- 2013/05/01 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2013/04/08 00:00 [pmc-release]
AID - dddt-7-297 [pii]
AID - 10.2147/DDDT.S43092 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2013 Apr 8;7:297-303. doi: 10.2147/DDDT.S43092. Print 2013.